Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 416 publications

Selpercatinib for RET fusion-positive non-small cell lung cancer.

Selpercatinib for RET fusion-positive non-small cell lung cancer.

Journal: Australian prescriber
Published: August 27, 2025

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.

The Utility of Tissue-Agnostic Drugs in Lung Cancer Treatment.

Journal: Pharmaceutical medicine
Published: August 26, 2025

KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer.

KEAP1 mutations activate the NRF2 pathway to drive cell growth and migration, and attenuate drug response in thyroid cancer.

Journal: bioRxiv : the preprint server for biology
Published: August 20, 2025

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.

Patient-Reported Tolerability of Selpercatinib Compared to Cabozantinib/Vandetanib: A Secondary Analysis of the LIBRETTO-531 Randomized-Controlled Trial in RET-Mutant Medullary Thyroid Cancer.

Journal: Thyroid : official journal of the American Thyroid Association
Published: August 19, 2025

A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene-Positive Non-Small Cell Lung Cancer.

A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene-Positive Non-Small Cell Lung Cancer.

Journal: Respirology case reports
Published: August 18, 2025

Selpercatinib in the treatment of thyroid cancer.

Selpercatinib in the treatment of thyroid cancer.

Journal: Future oncology (London, England)
Published: July 10, 2025

A Case of Micro-medullary Thyroid Carcinoma Presenting as Cancer of Unknown Primary.

A Case of Micro-medullary Thyroid Carcinoma Presenting as Cancer of Unknown Primary.

Journal: Cureus
Published: June 30, 2025

A Case Report on Pericardial Effusion Associated With Selpercatinib in the First Patient With Rearranged During Transfection (RET) Fusion-Positive Lung Cancer.

A Case Report on Pericardial Effusion Associated With Selpercatinib in the First Patient With Rearranged During Transfection (RET) Fusion-Positive Lung Cancer.

Journal: Cureus
Published: June 18, 2025

Inhibitory Effects of Vandetanib on Catecholamine Synthesis in Rat Pheochromocytoma PC12 Cells.

Inhibitory Effects of Vandetanib on Catecholamine Synthesis in Rat Pheochromocytoma PC12 Cells.

Journal: International journal of molecular sciences
Published: June 14, 2025

Case Report: Histological Transformation to Atypical Carcinoid in RET Fusion-positive NSCLC Following Immune Therapy Resistance

Case Report: Histological Transformation to Atypical Carcinoid in RET Fusion-positive NSCLC Following Immune Therapy Resistance

Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: June 12, 2025

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.

Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025

An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present).

An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present).

Journal: Expert opinion on therapeutic patents
Published: June 12, 2025
Showing 1-12 of 416

Last Updated: 10/31/2025